Lower Urinary Tract Cancer

Cannon, Claire M.; Allstadt, Sara D.

doi:10.1016/j.cvsm.2015.02.008

Cited by 22 publications

(27 citation statements)

References 91 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Currently, the veterinary oncology standard for the treatment of TCC in dogs is systemic medical therapy comprised of chemotherapy, cyclooxygenase inhibitors or combination of these [1,10,12]. Although medical therapy is not usually curative, remission or stable disease can be accomplished with several different drugs [1,11].…”

Section: Introductionmentioning

confidence: 99%

“…Surgery as a treatment option for TCC in the urinary bladder is used to obtain the tissue sample for histopathology, to attempt cancer removal from the bladder or to restore urine fl ow [12]. Radiation could also be used but to a lesser extent due to the complications including cystitis, urinary incontinence, colitis and colonic stricture [10,12].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The in Vitro and in Vivo Anti-Cancer Potential of Mycobacterium Cell Wall Fraction (MCWF) Against Canine Transitional Cell Carcinoma of the Urinary Bladder

Filion¹,

Rodrigues²,

Johannes

et al. 2017

Acta Veterinaria

View full text Add to dashboard Cite

Transitional cell carcinoma (TCC), is the most common form of urinary bladder cancer in dogs and represents 2% of all reported canine cancers. Canine TCC is usually a high-grade invasive cancer and problems associated with TCC include urinary tract obstruction and distant metastases in more than 50% of affected dogs. TCC is most commonly located in the trigone region of the bladder precluding complete surgical resection. Current treatment options for TCC in dogs include medical therapy, surgery or radiation. Mycobacterium Cell Wall Fraction (MCWF) is a biological immunomodulator derived from non-pathogenic Mycobacterium phlei. MCWF possesses a potential in multiple veterinary areas such as anticancer therapy, palliative care and treatment of infectious diseases in both small and large animals. MCWF is considered a bifunctional anti-cancer agent that induces apoptosis of cancer cells and stimulates cytokine and chemokines synthesis by cells of the immune system. Here we report the results from in vitro and in vivo studies that could suggest use of MCWF as an additional treatment option for TCC in dogs. Particularly, we demonstrated that MCWF induces a concentration dependent inhibition of proliferation of K9TCC cells which was associated with the induction of apoptosis as measured by the proteolytic activation of caspase-3 and the degradation of PARP. Furthermore, we demonstrated the safety and potential for in vivo MCWF treatment effi cacy in dogs bearing stage T2 TCC by reducing clinical signs, and improving the quality of life in dogs with TCC.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

The in Vitro and in Vivo Anti-Cancer Potential of Mycobacterium Cell Wall Fraction (MCWF) Against Canine Transitional Cell Carcinoma of the Urinary Bladder

Filion¹,

Rodrigues²,

Johannes

et al. 2017

Acta Veterinaria

View full text Add to dashboard Cite

show abstract

“…Über die medikamentöse Therapie mit einem NSAID und die traditionelle oder metronomische Chemotherapie hinaus kann eine lokale Therapie des ÜZK die Überlebenszeit deutlich verlängern (28,45). Für die externe Strahlentherapie wird vor der CT-Planung der Einsatz eines SEMS empfohlen (▶ Abb.…”

Section: üBergangszellkarzinom (üZk)unclassified

Minimal-invasive interventionelle Verfahren am Urogenitaltrakt von Hund und Katze

Heilmann¹

2016

Tierarztl Prax Ausg K

View full text Add to dashboard Cite

KeywordsBypass, stent, endoscopy, interventional radiology, catheter, obstruction, stricture SummaryMinimally invasive interventional techniques are advancing fast in small animal medicine. These techniques utilize state-of-the-art diagnostic methods, including fluoroscopy, ultrasonography, endoscopy, and laparoscopy. Minimally invasive procedures are particularly attractive in the field of small animal urology because, in the past, treatment options for diseases of the urogenital tract were rather limited or associated with a high rate of complications. Most endourological interventions have a steep learning curve. With the appropriate equipment and practical training some of these procedures can be performed in most veterinary practices. However, most interventions require referral to a specialty clinic. This article summarizes the standard endourological equipment and materials as well as the different endourological interventions performed in dogs and cats with diseases of the kidneys/renal pelves, ureters, or lower urinary tract (urinary bladder and urethra). Korrespondenzadresse

show abstract

“…Canine prostate adenocarcinoma (PAC) and transitional cell carcinoma (TCC) both show highly invasive growth and metastatic behavior that limit treatment options [7,8]. Several cytostatic drugs and cyclooxygenase 2 (COX-2) inhibitors appear to prolong survival times in TCC patients [8,9], whereas few studies support slight effects of COX-2 inhibitors solely or combined with chemotherapeutic agents against canine PAC [10,11]. Comparable to human castrate-resistant prostate cancer, canine PAC is mostly androgen-independent and therefore refractory to androgen depriving or suppressing treatments [7,12].…”

Section: Introductionmentioning

confidence: 99%

“…Differentiation between PAC and TCC in prostatic tumors is recommended [20,26], as further research might discover differences in therapeutic options and prognosis. However, a clear distinction based on clinical imaging, cytology, histopathology and molecular markers is still challenging [9,[27][28][29][30].…”

Section: Introductionmentioning

confidence: 99%

Characterization of six canine prostate adenocarcinoma and three transitional cell carcinoma cell lines derived from primary tumor tissues as well as metastasis

et al. 2020

View full text Add to dashboard Cite

Canine prostate adenocarcinoma (PAC) and transitional cell carcinoma (TCC) of prostate and urinary bladder are highly invasive and metastatic tumors of closely neighbored organs. Cell lines are valuable tools to investigate tumor mechanisms and therapeutic approaches in vitro. PAC in dogs is infrequent, difficult to differentiate from TCC and usually characterized by poor prognosis, enhancing the value of the few available cell lines. However, as cell lines adapt to culturing conditions, a thorough characterization, ideally compared to original tissue, is indispensable. Herein, six canine PAC cell lines and three TCC cell lines were profiled by immunophenotype in comparison to respective original tumor tissues. Three of the six PAC cell lines were derived from primary tumor and metastases of the same patient. Further, two of the three TCC cell lines were derived from TCCs invading into or originating from the prostate. Cell biologic parameters as doubling times and chemoresistances to commonly used drugs in cancer treatment (doxorubicin, carboplatin and meloxicam) were assessed. All cell lines were immunohistochemically close to the respective original tissue. Compared to primary tumor cell lines, metastasis-derived cell lines were more chemoresistant to doxorubicin, but equally susceptive to carboplatin treatment. Two cell lines were multiresistant. COX-2 enzyme activity was demonstrated in all cell lines. However, meloxicam inhibited prostaglandin E2 production in only seven of nine cell lines and did neither influence metabolic activity, nor proliferation. The characterized nine cell lines represent excellent tools to investigate PAC as well as TCC in prostate and urinary bladder of the dog. Furthermore, the profiled paired cell lines from PAC primary tumor and metastasis provide the unique opportunity to investigate metastasis-associated changes PAC cells undergo in tumor progression. The combination of nine differently chemoresistant PAC and TCC cell lines resembles the heterogeneity of canine lower urinary tract cancer. Funding: The authors wish to thank the Studienstiftung des Deutschen Volkes for supporting EMP with a scholarship. This publication was supported by Deutsche Forschungsgemeinschaft and University of PLOS ONE Canine prostate and bladder cancer cell lines derived from primary tumor and metastasis PLOS ONE | https://doi.org/10.Original tissue (P = Prostate, B = urinary bladder, Ln = lymph node); cell lines' names are explained as institution (Tiho = University of Veterinary Medicine Hannover); species (D = dog); tissue origin (Pro = prostate; Urt = urinary tract (urinary bladder)); diagnosis (Adcarc = adenocarcinoma; Carc = carcinoma; Metadcarc = metastasis of an adenocarcinoma); abbreviations of cell lines written in bold; none = cell lines have not been published yet; n.a. = tissue of patient no. 5 is missing, as the patient owners declined surgery and necropsy; � diagnosis by cytology of cells obtained by fine needle aspiration biopsy.

show abstract

Lower Urinary Tract Cancer

Cited by 22 publications

References 91 publications

The in Vitro and in Vivo Anti-Cancer Potential of Mycobacterium Cell Wall Fraction (MCWF) Against Canine Transitional Cell Carcinoma of the Urinary Bladder

The in Vitro and in Vivo Anti-Cancer Potential of Mycobacterium Cell Wall Fraction (MCWF) Against Canine Transitional Cell Carcinoma of the Urinary Bladder

Minimal-invasive interventionelle Verfahren am Urogenitaltrakt von Hund und Katze

Characterization of six canine prostate adenocarcinoma and three transitional cell carcinoma cell lines derived from primary tumor tissues as well as metastasis

Contact Info

Product

Resources

About